(Posted By: Josi Creek)
Investment bank UBS has predicted there could be a "surge" in the number of patients using Elan's Tysabri multiple sclerosis drug that develop a life-threatening brain disease known to be the most serious side-effect of the treatment. UBS has advised investors to sell Elan shares.
About 46 cases of PML have been detected in patients using Tysabri over the past few years, while 11 people have died from the disease. Some of those who survive are left requiring considerable long-term medical care. Some 50,300 people were using Tysabri as of the end of last month, half of them in the US.
To read the entire story, click HERE
